140 related articles for article (PubMed ID: 26068771)
1. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
Mahipal A; Denson AC; Djulbegovic B; Lush R; Kumar A; Juan TH; Schell MJ; Sullivan DM
Cancer Control; 2015 Apr; 22(2):235-41. PubMed ID: 26068771
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial outcomes in older patients with advanced solid tumours.
Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
[TBL] [Abstract][Full Text] [Related]
3. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
Buechel M; McGinnis A; Vesely SK; Wade KS; Moore KN; Gunderson CC
Gynecol Oncol; 2018 Apr; 149(1):28-32. PubMed ID: 29605046
[TBL] [Abstract][Full Text] [Related]
4. Do elderly patients benefit from enrollment into Phase I Trials?
Tai WM; Lim C; Ahmad A; Ong WS; Choo SP; Lim WT; Tan EH; Kanesvaran R; Tan DS
J Geriatr Oncol; 2015 May; 6(3):241-8. PubMed ID: 25779876
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies.
Ao G; de Miguel M; Gomes A; Liu R; Boni V; Moreno I; Cárdenas JM; Cubillo A; Ugidos L; Calvo E
Invest New Drugs; 2021 Dec; 39(6):1694-1701. PubMed ID: 34287771
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
Gounder MM; Nayak L; Sahebjam S; Muzikansky A; Sanchez AJ; Desideri S; Ye X; Ivy SP; Nabors LB; Prados M; Grossman S; DeAngelis LM; Wen PY
J Clin Oncol; 2015 Oct; 33(28):3186-92. PubMed ID: 26282642
[TBL] [Abstract][Full Text] [Related]
8. Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals?
Balducci L
Cancer Control; 2015 Apr; 22(2):232-4. PubMed ID: 26068770
[No Abstract] [Full Text] [Related]
9. Aspects of survival from colorectal cancer in Denmark.
Iversen LH
Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR
Breast Cancer Res Treat; 2018 Feb; 168(1):35-41. PubMed ID: 29119354
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.
Cuffe S; Booth CM; Peng Y; Darling GE; Li G; Kong W; Mackillop WJ; Shepherd FA
J Clin Oncol; 2012 May; 30(15):1813-21. PubMed ID: 22529258
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
[TBL] [Abstract][Full Text] [Related]
13. Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
Zeidner JF; Karp JE; Blackford AL; Foster MC; Dees EC; Smith G; Ivy SP; Harris P
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26553781
[TBL] [Abstract][Full Text] [Related]
14. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011.
Rowe J; Patel S; Mazo-Canola M; Parra A; Goros M; Michalek J; Kelly K; Weitman S; Karnad A
J Geriatr Oncol; 2014 Jan; 5(1):65-70. PubMed ID: 24484720
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Horstmann E; McCabe MS; Grochow L; Yamamoto S; Rubinstein L; Budd T; Shoemaker D; Emanuel EJ; Grady C
N Engl J Med; 2005 Mar; 352(9):895-904. PubMed ID: 15745980
[TBL] [Abstract][Full Text] [Related]
17. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.
Benajiba L; Michot JM; Baldini C; Faivre L; Varga A; Balheda R; Gazzah A; Ileana E; Postel-Vinay S; Massard C; de Botton S; Soria JC; Ribrag V
Anticancer Drugs; 2017 Jun; 28(5):540-545. PubMed ID: 28225458
[TBL] [Abstract][Full Text] [Related]
19. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials.
Bachelot T; Ray-Coquard I; Catimel G; Ardiet C; Guastalla JP; Dumortier A; Chauvin F; Droz JP; Philip T; Clavel M
Ann Oncol; 2000 Feb; 11(2):151-6. PubMed ID: 10761748
[TBL] [Abstract][Full Text] [Related]
20. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
